نتائج البحث

1

دورية أكاديمية

المؤلفون: Papamargaritis, Dimitris, le Roux, Carel W., Holst, Jens J., Davies, Melanie J.

المصدر: Papamargaritis , D , le Roux , C W , Holst , J J & Davies , M J 2023 , ' New therapies for obesity ' , Cardiovascular Research , vol. 119 , no. 18 , pp. 2825–2842 . https://doi.org/10.1093/cvr/cvac176Test

مصطلحات موضوعية: Obesity, Pharmacotherapy, Bariatric surgery, Semaglutide, Tirzepatide, Liraglutide, LIFE-STYLE INTERVENTION, GLP-1 RECEPTOR AGONIST, LIRAGLUTIDE 3.0 MG, QUALITY-OF-LIFE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE, CARDIOVASCULAR RISK-FACTORS, TYPE-2 DIABETES-MELLITUS, WEIGHT-LOSS MAINTENANCE, SEMAGLUTIDE 2.4 MG, POST-HOC ANALYSIS

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1093/cvr/cvac176Test
https://curis.ku.dk/portal/da/publications/new-therapies-for-obesityTest(fb5cf258-378c-47c0-b65f-a2609743b2ee).html
https://curis.ku.dk/ws/files/386364682/New_therapies_for_obesity.pdfTest

View record in BASE

2

دورية أكاديمية

Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland

المؤلفون: Christiane Lundegaard Haase, Maria Giovanna Serratore Achenbach, Gianluca Lucrezi, Nikita Jeswani, Susanne Maurer, Ulrich Egermann

المصدر: Obesity Facts, Pp 1-9 (2021)

مصطلحات موضوعية: liraglutide 3.0 mg, weight loss, glucagon-like peptide-1 receptor agonist, bariatric surgery, electronic medical records, Nutrition. Foods and food supply, TX341-641, Nutritional diseases. Deficiency diseases, RC620-627

وصف الملف: electronic resource

العلاقة: https://www.karger.com/Article/FullText/518325Test; https://doaj.org/toc/1662-4025Test; https://doaj.org/toc/1662-4033Test

الوصول الحر: https://doaj.org/article/ba65a9c9d71c43dfa469135a8bd66731Test

View record in DOAJ

النص الكامل

3

دورية أكاديمية

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program

المؤلفون: Sean Wharton, Christiane L Haase, Elham Kamran, Aiden Liu, Johanna Mancini, Drew Neish, Arash Pakseresht, G Sarah Power, Rebecca AG Christensen

المصدر: Obesity Science & Practice, Vol 6, Iss 4, Pp 382-389 (2020)

مصطلحات موضوعية: Liraglutide 3.0 mg, obesity, persistence, SaxendaCare®, Internal medicine, RC31-1245

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2055-2238Test

الوصول الحر: https://doaj.org/article/b1e41395ee644095b92b842ca20e8a0bTest

View record in DOAJ

النص الكامل

4

دورية أكاديمية

EFFECT OF BA AND TDZ IN VEGETATIVE MULTIPLICATION OF SHOOT TIPS AND NODES OF Buahinia purpurea L. In vitro

المؤلفون: Sumood Alhadeedy, Evet A. Youhannan

المصدر: Mesopotamia Journal of Agriculture, Vol 46, Iss 2, Pp 238-247 (2018)

مصطلحات موضوعية: this study aimed to develop a system for propagating of camel's foot bauhinia purpurea l. by tissue culture technology. seeds were germinated after removal the external coats in agar-solidified ms medium without growth regulators, in order to get fresh explants and sterilized for use in the following study stages. after 4 weeks of germination and a suitable high of seedlings explants from growing tips and nodes were excised and cultured in ms medium supplemented with different, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 mg/l) of each during initiation and replication stages in order to get a highest number of multiplied new shoots, cultured growing tips showed that 1.5 mg/l of ba produced the shoots numerous average 2.66 using 2.5 and 3.0 mg/l of tdz also have largest shoots average 3.10. on the other hand, nodes cultured on 3.0 mg/l ba have highest shoots average 6.44 at a time tdz with concentration of 2.0 mg/l also have highest shoots number 7.44. results showed in multiplication stage for growing tips and nodes which we have from initiation stage cu, Agriculture

وصف الملف: electronic resource

العلاقة: https://magrj.mosuljournals.com/article_161464_65ad29269abd13803a35faf01580e917.pdfTest; https://doaj.org/toc/1815-316XTest; https://doaj.org/toc/2224-9796Test

الوصول الحر: https://doaj.org/article/adf424bcf95644ee9fb58db88982750cTest

View record in DOAJ

5

دورية أكاديمية

EFFECT OF NAA, IBA AND MS STRENGTH IN ROOTING OF Bauhinia purpurea L. IN VITRO

المؤلفون: Sumood Alhadeedy, Evet Adward Youhannan

المصدر: Mesopotamia Journal of Agriculture, Vol 45, Iss 4, Pp 159-166 (2017)

مصطلحات موضوعية: this study aimed to assess the effect of concentrations 0.0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0 mg/l of each of iba and naa and ms strength in shoot rooting of purple camel's foot the plantlet produced from the buds in multiplication stage on ms with 3.0 mg/l ba or 2.0 mg/l tdz. rooting results using full strength ms medium showed that 0.75, so 1.5 mgl iba have highest numbers of roots (9.88) and longest roots trait (25.05 cm.). but 3.0 mg/l naa was superior in comparison with all the other concentrations and have largest numbers for shoots with recorde (11.66), but 0.25 mgl naa gave highest roots (15.77). in this study it was possible to acclimatized the plant growing in tubes, plantlets were hardened gradually by removed the plantlets from the tubes washing them thoroughly with water to remove the residual agar from the roots, then planted in pots containing mixture of sand and petmous (1:1). and covered with light permeable plastic sheets with pores to inter air. percentage (80%) was achieved, Agriculture

وصف الملف: electronic resource

العلاقة: https://magrj.mosuljournals.com/article_161378_51276653712303a7b3f84c4ef0b0c31b.pdfTest; https://doaj.org/toc/1815-316XTest; https://doaj.org/toc/2224-9796Test

الوصول الحر: https://doaj.org/article/959df154ff3547f0b9f3f79fe53e9943Test

View record in DOAJ

6

دورية أكاديمية

SGLT2 inhibitors and GLP-1 receptor agonists:established and emerging indications

المؤلفون: Brown, Emily, Heerspink, Hiddo J. L., Cuthbertson, Daniel J., Wilding, John P. H.

المصدر: Brown , E , Heerspink , H J L , Cuthbertson , D J & Wilding , J P H 2021 , ' SGLT2 inhibitors and GLP-1 receptor agonists : established and emerging indications ' , LANCET , vol. 398 , no. 10296 , pp. 262-276 . https://doi.org/10.1016/S0140-6736Test(21)00536-5

مصطلحات موضوعية: GLUCOSE-LOWERING DRUGS, ONCE-DAILY LIRAGLUTIDE, OPEN-LABEL, CARDIOVASCULAR OUTCOMES, DOUBLE-BLIND, CVD-REAL, CONTROLLED-TRIAL, EXENATIDE TWICE, ITCA 650, 3.0 MG